The next-generation screening test of Geneoscopy is a multi-target stool RNA biomarker panel, designed to identify colorectal cancer and precancerous lesions
Geneoscopy inks a multi-year distribution deal for its colorectal cancer screening test with Labcorp. (Credit: Laboratory Corporation of America® Holdings)
Geneoscopy, a life sciences company-focused on gastrointestinal health, has entered into a multi-year partnership with Labcorp for the distribution of its colorectal cancer screening test by the laboratory services provider.
The next-generation screening test involved in the collaboration is a multi-target stool RNA (mt-sRNA) biomarker panel. It is designed to identify colorectal cancer and precancerous lesions.
The mt-sRNA test is said to provide at-home collection and high sensitivity for early cancer detection. It is currently under the US Food and Drug Administration (FDA) review.
After receiving FDA approval, Labcorp will make the test available, which will be carried out by Geneoscopy.
The partnership will enable health care customers to quickly obtain the test through Labcorp as part of their comprehensive screening programmes.
Geneoscopy chief commercial officer Vince Wong said: “Colorectal cancer is one of the most preventable cancers, yet millions of eligible Americans do not get screened as directed by guidelines.
“Working with Labcorp, an organisation trusted daily by thousands of clinicians and millions of patients, is an incredible opportunity to expand patient and clinician access to our noninvasive screening test.
“Given Labcorp’s extensive access to communities across the country, we believe this collaboration will help reduce the barriers to screening and address health inequities.”
The life sciences firm plans to submit a premarket approval application (PMA) to the FDA based on the positive outcomes of the CRC-PREVENT study.
In the trial, Geneoscopy’s test showed high sensitivity for colorectal cancer and advanced adenomas.
Additionally, the sensitivity for colorectal cancer was 100% for participants who were between 45 to 49 years of age.
Labcorp chief medical and scientific officer Brian Caveney said: “This agreement builds on Labcorp’s commitment to bring the latest advancements in cancer screening and diagnostic testing to healthcare providers and patients.
“Geneoscopy’s highly sensitive colorectal cancer screening test, once approved, will be another innovative, accessible and reliable option available to providers and patients nationwide for the detection of colorectal cancer.”